DuPont de Nemours, Inc. (DD) completed the divestiture of its Aramids business, which includes the Kevlar® and Nomex® brands, to Arclin, a portfolio company of TJC, L.P., on April 1 2026. The transaction was valued at approximately $1.8 billion and gave DuPont pre‑tax cash proceeds of about $1.2 billion, a $300 million note receivable, and a non‑controlling equity stake in Arclin worth roughly $325 million, representing about 16% of the company.
The sale removes a legacy, low‑margin, capital‑intensive segment that had been reclassified as discontinued operations beginning in the third quarter of 2025. In 2024 the Aramids business generated net sales of $1.3 billion, and its low margin profile had weighed on DuPont’s overall profitability. By divesting the unit, DuPont now has a net‑debt‑free balance sheet and an estimated $500 million of deployable free cash flow each year, positioning the company to pursue acquisitions in high‑growth specialty industrial areas such as healthcare and water.
Analysts reacted positively to the transaction. BMO Capital raised its price target on DuPont to $60, citing the company’s sharpened focus on higher‑margin businesses, while RBC Capital increased its target to $161. Over the six months leading up to the sale, DuPont’s stock had risen 41–42%, reflecting investor confidence in the portfolio transformation strategy.
"Today's announcement is another important step in our continued optimization of the new DuPont portfolio. The Aramids transaction further enhances the strategic focus of our portfolio, while also increasing the growth and margin profile," said DuPont CEO Lori Koch. She added, "The transaction is structured to maximize value for our shareholders by providing significant cash proceeds at close which will be re‑deployed to further drive value creation, while also allowing DuPont shareholders to participate in Arclin's growth potential through our retained equity interest."
Mark Glaspey, Arclin President, said, "Kevlar® and Nomex® are the gold standard in their respective industries, and we are very excited to incorporate the Aramids platform into Arclin's broader material science portfolio. This acquisition strategically strengthens Arclin's operational and geographic footprint. With established manufacturing operations in Europe and Asia and ~1,800 new team members around the world, we are focused on operational continuity from day one while investing in manufacturing capabilities and innovation to support long‑term growth."
The deal marks the final major surgery in DuPont’s portfolio transformation, freeing capital for growth and allowing the company to focus on specialty industrial businesses with higher margins. For Arclin, the acquisition expands its scale and capabilities in life‑critical industries and provides a significant equity stake that aligns the interests of both companies moving forward.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.